Overall survival results of AGO-OVAR16: a phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer

Nom du journal : Gynecol Oncol

Année : 2019

Volume : 155

Page de départ : 186

Page de fin : 191

Auteurs: Meunier J, Harter P, Herzog TJ, Monk BJ, Mirza MR, Colombo N, Fujiwara K, Pignata S, del Campo JM, Rau J, Kim JW, du Bois A, Friedlander M, Vergote I, Floquet A, Tsibulak I, Calvert PM, Hanker LC, Lee JY, Bologna A, Carrasco-Alfonso MJ,